Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07003074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Name: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer — clinical trial record (NCT07003074)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Started2025-06-23

View on ClinicalTrials.gov ↗

Amendment history

2025-06-24

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-08→confirmed 2025-06-23

Study sitesdetails revised at 25 of 25 sites

2025-06-02

Original filing

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

38 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.

Trial Details

NCT Number	NCT07003074
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions	Breast Cancer
Enrollment	642 participants
Start Date	2025-06-23
Primary Completion	2029-07 (estimated)
Study Completion	2030-07 (estimated)
Updated on ClinicalTrials.gov	2025-06-25